#$%^&*AU2020203066A120200528.pdf#####Abstract Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and 5 their use in the treatment of cancer. 12328552_1 (GHMatters) P111428.AU.18/33 (0 d U... ....... a, 0~ cm L a C Ca) ~'E CL: C U)a ~ ,a ot Eo)D ' C 0 ~ co o o 0 4- =~ . a, a . 0coc C1, 0.... - - C m U) (L -. 4 0->； 1 a, 0 -0 =C) 00 Z -e C - -0 Ct "--.-c z0.V-ooo L~ C)a)4 0 E. -Ox na) AlojeS puB SOi1GUllOOeWJqd JUaWSSaSSV c: Coq U). .C~~ ~U '6 U) .C C U). ac a, a, ac a UL.. T ) c m WU ； *a,*a,) a.0O
